2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2152

Inhibition of Fucose Incorporation Abrogates the Development of Arthritis by Suppressing the Inflammatory Macrophage Development and TNF-α Production
Abstract Number: 736

Inhibition of Interleukin-17 Signaling Via De-Ubiquitinatio
Abstract Number: 2517

Inhibition of Notch Signaling Increases the Severity of Experimental Osteoarthritis
Abstract Number: 2575

Inhibition of Pathogenic Autoantibodies by Accelerating the Exit of Germinal Center B Cells Via Manipulation of Regulator of G-Protein Signaling
Abstract Number: 44

Inhibition of WNT Signaling Pathway by Sclerostin Maintains Cartilage Homeostasis
Abstract Number: 1603

Inhibitor of DNA Binding 1 As a Secreted Angiogenic Transcription Factor in Rheumatoid Arthritis
Abstract Number: 2008

Initial Evaluation of a Localized Scleroderma (LS) Clinical Activity Measure
Abstract Number: 360

Initial Introduction of Treat-to-Target Strategy in Patients with Recent Onset Rheumatoid Arthritis Is More Effective Than Delayed Introduction of Strategy with More Clinical and Functional Remission Achieved for 2-Years: Results of the Treating to Twine Targets (T-4) Study
Abstract Number: 2437

Initiating an Innovative Training Programme to Improve Access to Musculoskeletal Health Care in Kenya
Abstract Number: 1960

Initiation of Tumor Necrosis Factor Alpha (TNFα) Antagonists and Risk of Fractures in Patients with Selected Rheumatic and Autoimmune Diseases
Abstract Number: 2433

Integration of a Healthy Aging Program Into the Arthritis Foundation Exercise Program: Six-Month Results
Abstract Number: 439

Interaction of Antibodies Against Citrullinated Peptides with HLA Shared Epitope, PTPN22 1858T Variant, and Smoking in Individuals Prior to and After the Development of Rheumatoid Arthritis
Abstract Number: 681

Interferon Alpha Decreases Endothelial Nitric Oxide Synthase Function and Expression in Human Umbilical Vein Endothelial Cells
Abstract Number: 2668

Interferon and B-Cell Gene Signatures Contribute to Diagnosis of pre-Clinical Rheumatoid Arthritis
Abstract Number: 843

Interferon Regulatory Factor 5 Associates with Systemic Lupus Erythematosus Through Two Distinct and Independent Effects

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].